The approval marks a significant milestone in VibroSense Dynamics’ global growth strategy and opens up new business opportunities in one of the world's fastest-growing medical technology markets. China currently has over 140 million people living with diabetes, creating a massive need for early diagnosis and monitoring of peripheral nerve damage – an area where VibroSense Meter® II offers unique diagnostic precision.

“This is a major success for us. The NMPA approval is the result of extensive regulatory work and confirms the high quality and safety of our technology. It opens the door to a market with enormous potential and enables us to contribute to better care for millions of people in China,” says Tarik Cengiz, CEO of VibroSense Dynamics AB.

The company is now preparing for market launch together with its exclusive Chinese partner, UMCARE. In February 2022, VibroSense signed a distribution agreement with UMCARE, granting them an exclusive, time-limited right to sell VibroSense Meter® II throughout China for three years. The agreement also includes a binding order worth EUR 3.8 million, with scheduled deliveries over the three-year period.

For more information, please contact:
Tarik Cengiz, CEO
VibroSense Dynamics AB (publ)
Phone: +46 40 88 026
Email: info@vibrosense.com
Website: www.vibrosense.com

“The new Gold Standard for reliable
 detection of nerve damage”

About VibroSense Dynamics AB (publ)
VibroSense Dynamics AB (publ) develops and sells medical devices and services to support the diagnosis of nerve damage in the hands and feet. The method is based on measuring and quantifying the ability to sense vibrations at multiple frequencies. The company's customers include diabetes clinics, occupational health providers, hospitals, primary care centers, and researchers.
Our vision is for the company's products to become a standard tool in all neurological examinations, helping to detect early signs of sensory changes so that patients and healthcare providers can take preventive action to avoid, reduce, or delay the onset of nerve damage in the hands and feet.